Motion-retaining spinal implants set back by insufficient clinical efficacy

29 May 2017 (Last Updated November 22nd, 2018 11:32)

As orthopedic therapies advance, retention of motion and an independent lifestyle has been an increasing concern among patients, particularly the growing global elderly population.

Motion-retaining spinal implants set back by insufficient clinical efficacy

As orthopedic therapies advance, retention of motion and an independent lifestyle has been an increasing concern among patients, particularly the growing global elderly population.

Spinal nonfusion devices have emerged as an alternative to the traditional spinal fusion procedure to maintain spinal motion and flexibility.

These nonfusion devices include cervical and lumbar artificial disc replacement (ADR) systems, interspinous process decompression (IPD) devices, and pedicle screw-based dynamic stabilisation systems. They evoked interest in their infancy, but their promise has tapered in the wake of insufficient clinical efficacy.

Only cervical artificial disc replacement systems have collected a body of evidence ample enough to support their use beyond investigational status in the US and as a viable treatment option in Europe. These devices are expected to drive growth in the spinal nonfusion market over the next five years.

GlobalData estimates the global spinal nonfusion market was valued at $696m in 2016 and is expected to grow to $1.3bn in 2023 propelled by the adoption of cervical ADR systems. Long-term clinical evidence supporting the use of IPD devices and pedicle screw-based dynamic stabilisation systems is vital to the continued evolution of this market, as patients continue to seek an active, mobile lifestyle.

GlobalData report: Artificial Disc Replacement - North America Analysis and Market Forecasts